Deaths, permanent injuries and life-threatening reactions have been hidden, dismissed and minimized by scientists working for the vaccines' manufacturers. They've also played a scientific sleight of hand by adding aluminium (US: aluminum), a neurotoxin, to the placebo, so reducing the ratio of reported reactions to the actual vaccine.
Yet, despite testing the vaccines against aluminium placebos, more young girls died after being vaccinated; 14 of the 2,881 who were vaccinated died afterwards compared to three given the placebo. And 3 per cent—or 212 girls—of the 7,071 given the highest dose of the HPV jab suffered a serious adverse reaction.
Researchers from the National Institute of Cardiology in Mexico took another look at 28 studies that explored the impact of the three HPV vaccines that have been on the market up to last January.
Only two of the 16 randomized trails—where a placebo is tested against the active drug—only two used an inert saline solution; the rest added aluminium to the placebo, thus increasing the chance that a patient will react to it.
Independent safety trials have borne out the researchers' findings. Spanish researchers discovered a 10-fold higher rate of adverse reactions compared to other vaccines, while Canadian scientists concluded that one in 10 people vaccinated with the HPV need emergency hospital treatment within 42 days of vaccination.
The vaccine is given to protect against cervical cancer.